AdvaMed Responds to DOJ’s Anticompetitive Regulations Inquiry
In response to the Department of Justice’s Anticompetitive Regulations Task Force Request for Comments, AdvaMed has outlined how outdated and overly burdensome regulations are hindering innovation and access in the medtech industry. This public comment advocates for reform that supports small businesses, promotes entrepreneurship, and improves patient care—especially in underserved communities.
The U.S. health care system is transitioning from a fee-for-service model to a value-based paradigm to deliver more coordinated, high-quality, and affordable health care. AdvaMed is leading the way in promoting value-based collaborations that advance patient care and improve health outcomes.
AdvaMed’s efforts include updating its Code of Ethics to reflect the changing landscape of the medtech industry. Recent revisions to the Code aim to promote transparency and compliance while fostering innovation and access to safe and effective medical technologies.
By advocating for regulatory reform and promoting value-based collaborations, AdvaMed is working to create a more favorable environment for medical technology innovation and timely patient access to life-saving treatments.
